Compare MRT & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRT | MDWD |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | Turkey | Israel |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.4M | 162.2M |
| IPO Year | 2021 | 2013 |
| Metric | MRT | MDWD |
|---|---|---|
| Price | $1.86 | $11.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $5.04 | ★ $30.67 |
| AVG Volume (30 Days) | 46.2K | ★ 63.2K |
| Earning Date | 08-08-2018 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $116.52 | $39.60 |
| Revenue Next Year | $59.73 | $34.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.12 | $11.87 |
| 52 Week High | $2.75 | $20.03 |
| Indicator | MRT | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 45.37 | 32.52 |
| Support Level | $1.60 | N/A |
| Resistance Level | $1.87 | $14.06 |
| Average True Range (ATR) | 0.10 | 0.42 |
| MACD | -0.01 | -0.15 |
| Stochastic Oscillator | 33.26 | 3.69 |
Marti Technologies Inc is Turkiye's urban mobility platform, helping to solve the country's transportation needs through tech-enabled services powered by a single mobility super app. The Group aims to offer tech-enabled urban transportation services to consumers across Turkiye through three service offerings: ride-hailing, delivery, and two-wheeled electric vehicle services. The Group's ride-hailing service matches consumers with car, motorcycle, and taxi drivers. The Group's delivery service provides same-hour package delivery by leveraging the Group's existing network of car and motorcycle drivers and consumer base.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.